Real-world Study of Biological Treatments for Adults with Chronic Rhinosinusitis and Nasal Polyps

What this Trial Is About

This observational study focuses on patients with chronic rhinosinusitis with nasal polyps CRSwNP, a condition affecting 5-10% of adults and often linked to asthma and aspirin exacerbated respiratory disease. Researchers aim to learn about the real-world effectiveness of biologic treatments in managing CRSwNP, especially since these treatments target specific inflammatory processes and their results in everyday settings may differ from controlled clinical trials. The study includes patients aged 18 and older who have CRSwNP and are eligible for reimbursement of biologic treatments such as omalizumab, mepolizumab, or dupilumab. These biologics are prescribed as add-on treatments to standard care. The study tracks patients over time to assess the impact of these biologics on nasal congestion, nasal polyps, symptom severity, quality of life, asthma control, sense of smell, and treatment adherence. Participants will be followed from enrollment through up to three years of treatment. Researchers will collect patient-reported outcomes using various questionnaires and nasal endoscopy to score nasal polyps. They will monitor nasal congestion scores and other clinical measures regularly to compare real-world treatment effects with those seen in clinical trials. This helps understand how well biologics work in typical clinical practice and for which patients they are most effective.

Real-life Evaluation of the Efficacy of Biologicals in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)